Traws Pharma, Inc. (TRAW)
| Market Cap | 26.67M +272.7% |
| Revenue (ttm) | 2.73M +1,104.0% |
| Net Income | -13.91M |
| EPS | -1.52 |
| Shares Out | 15.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 787,910 |
| Open | 1.880 |
| Previous Close | 1.880 |
| Day's Range | 1.732 - 1.917 |
| 52-Week Range | 0.995 - 3.265 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+212.5%) |
| Earnings Date | May 15, 2026 |
About TRAW
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TRAW stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 212.50% from the latest price.
News
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma files to sell 35.9M shares of common stock for holders
17:05 EDT Traws Pharma (TRAW) files to sell 35.9M shares of common stock for holders
There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.
It's been a struggle to secure funding for hantavirus research because these viruses haven't been a priority.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ta...
Traws Pharma Earnings Call Transcript: Q4 2025
Significant progress was made advancing a next-gen influenza antiviral, supported by $60M in new financing. Net income turned positive in 2025, and key clinical studies are planned in the UK, while US trials face an FDA clinical hold pending toxicology data resolution.
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir
Traws Pharma (TRAW) announced the completion of the clinical analysis of its 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, v...
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; res...
Traws Pharma initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says the company offers an alternative to Cidara’s CD388.
Traws Pharma completes enrollment in Phase 2 study of ratutrelvir
Traws Pharma (TRAW) announced the completion of enrollment in its ongoing 90-patient, open-label Phase 2 study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, vers...
Traws Pharma files tivoxavir marboxil IND application with U.S. FDA
Traws Pharma (TRAW) announced the filing of a U.S. IND application with the U.S. Food and Drug Administration, FDA, for tivoxavir marboxil, TXM, a CAP-dependent endonuclease inhibitor as a single…
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpil...
Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid
Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, demonstrated a differentiated clinical profile in a pre-specified...
Traws Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price target The company’s pipeline is led by two oral antivirals, ratutrelvir in…
Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year
Cash and cash equivalents: As of September 30, 2025, the Company had cash and cash equivalents of approximately $6.4 million, compared to approximately $21.3 million as of December 31, 2024.
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services c...
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 c...
Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies
Traws Pharma (TRAW) announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free anti-viral treatment in newly diagnosed COVID subjects. “The first trial…
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment
Traws Pharma appoints John Leaman as independent director
Traws Pharma (TRAW) announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws’ Board of Directors has…
Traws Pharma receives approval to proceed with Phase 2 COVID studies
Traws Pharma (TRAW) announced receipt from the Human Research Ethics Committee of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID…
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ®
Traws Pharma Earnings Call Transcript: Q2 2025
Advanced COVID-19 and influenza antiviral programs, with phase II ratutrelvir results expected by year-end 2025. Revenue rose sharply due to deferred licensing income, and net loss narrowed significantly year-over-year. Bird flu study deferred amid low incidence, but regulatory approvals position for rapid response.
Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year
Reports Q2 revenue $2.7M vs. $57,000 last year. “Traws has made good progress this year towards our goal of bringing our antiviral candidates to patients as soon as possible. We…
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM)